https://www.optimumcomms.com/wp-content/uploads/2023/02/CurveTx_Logo_300x180px-80x80-Recovered.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-09 08:37:022024-10-09 08:37:02Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum.png
180
300
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2024-10-08 12:45:442024-10-08 16:09:58Optimum Strategic Communications to Host 16th Annual Healthcare Investor Conference with ‘Back to Growth’ theme
https://www.optimumcomms.com/wp-content/uploads/2023/06/adcendo_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-08 08:36:272024-10-08 08:36:27Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-03 07:41:032024-10-03 07:44:16Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
https://www.optimumcomms.com/wp-content/uploads/2024/10/Loqus23_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-02 08:43:262024-10-02 10:27:03LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
https://www.optimumcomms.com/wp-content/uploads/2023/02/CurveTx_Logo_300x180px-80x80-Recovered.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-02 08:39:572024-10-02 08:39:57Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-01 17:00:442024-10-01 17:00:44Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-01 08:51:132024-10-01 08:51:13Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-01 08:35:152024-10-01 08:35:15Neuraxpharm expands operations into the Middle East
https://www.optimumcomms.com/wp-content/uploads/2023/10/Template_Logo_300x180px-80x80Web_Logos-5.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-10-01 08:34:092024-10-01 10:52:06AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
https://www.optimumcomms.com/wp-content/uploads/2023/02/Heidelberg_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-23 12:51:002024-09-23 12:51:00Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-23 08:32:402024-09-23 08:32:40Biocomposites to showcase innovations in infection management at EBJIS 2024
https://www.optimumcomms.com/wp-content/uploads/2024/09/Vicebio_Logo_300x180px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-23 08:24:562024-09-24 11:22:17Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine
https://www.optimumcomms.com/wp-content/uploads/2024/09/Renovos-logo.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-19 08:36:102024-09-19 10:40:46Renovos Biologics strengthens its Board’s US expertise with appointment of Lisa Ferrara
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-18 08:40:392024-09-18 08:40:39Poolbeg Pharma plc – Interim results for the six months to 30 June 2024
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-18 08:32:462024-09-18 08:32:46Biocomposites acquires remaining shares in manufacturers of SYNICEM™ and Subiton products
https://www.optimumcomms.com/wp-content/uploads/2024/09/Minervax_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-17 08:46:382024-09-19 10:41:25MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus
https://www.optimumcomms.com/wp-content/uploads/2023/02/Alchemab_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-12 13:14:262024-09-12 13:14:26Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
https://www.optimumcomms.com/wp-content/uploads/2024/09/QL-Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-12 10:56:122024-09-12 10:57:33QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel Once-Monthly GLP-1RA ZT002 at EASD 2024
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-09-12 08:36:132024-09-12 08:36:13Biocomposites to distribute its NanoBone® product range in the UKFor more information about Optimum Strategic Communications, please get in touch.
